Beyond oral antidiabetics: Insulin therapy options and combinations

Abstract Objective To describe the appropriate selection and use of recently approved insulin products. Data sources This article is based on the presentation Beyond Oral Antidiabetics: Insulin Therapy Options and Combinations, which was delivered by Stuart Haines, PharmD, BCPS, BCACP, BC-ADM, and Jennifer Trujillo, PharmD, BCPS, CDE, at the APhA 2017 Annual Meeting & Exposition in San Francisco, March 24–27, 2017. References were identified on the basis of articles cited in the presentation and supplemental research by the author. Summary Several insulin products have been approved in recent years that provide new treatment options for patients with diabetes, including both basal and prandial products. Some of these products have differences in pharmacodynamic profiles that allow for greater individualization of diabetes management. Collaboration with patients, including early and ongoing education on the role of insulin in diabetes therapy, can support patient acceptance of insulin therapy and adherence to treatment recommendations. Conclusion Insulin remains crucial to management of type 1 diabetes and is widely used for effective management of type 2 diabetes. New formulations of insulin provide pharmacists with additional options for tailoring patients' insulin regimens to their individualized needs. Careful product selection and dosage titration can improve glycemic control while minimizing risks associated with insulin use, such as hypoglycemia.